Elevated Serum IL-17 Expression at Cessation Associated with Graves' Disease Relapse

BACKGROUND: Antithyroid drug (ATD) treatment occupies the cornerstone therapeutic modality of Graves' disease (GD) with a high relapse rate after discontinuation. This study aimed to assess potential risk factors for GD relapse especially serum interleukin-17 (IL-17) expression. METHODS: Consec...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jianhui, Sun, Xiaohua, Yao, Danzhen, Xia, Jinying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866853/
https://www.ncbi.nlm.nih.gov/pubmed/29713343
http://dx.doi.org/10.1155/2018/5689030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866853/
https://www.ncbi.nlm.nih.gov/pubmed/29713343
http://dx.doi.org/10.1155/2018/5689030

Ejemplares similares